Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26048629 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRFKBP1AKDM4EHSD17B10 | |
| SCHEMBL7261536 | 0.95 | ALDH1A1 (0.56) | ALDH1A1TSHRKDM4EHSD17B10CYP1A2 | |
| SCHEMBL9525416 | 0.92 | ALDH1A1 (0.53) | ALDH1A1TSHRKDM4EHSD17B10CYP1A2 | |
| SCHEMBL19830987 | 0.91 | TSHR (0.49) | ALDH1A1TSHRFKBP1AFABP7FABP5 | |
| SCHEMBL28349165 | 0.86 | TSHR (0.46) | ALDH1A1TSHRFKBP1AFABP7FABP5 | |
| SCHEMBL28117364 | 0.81 | TSHR (0.47) | ALDH1A1TSHRFKBP1AFABP7FABP5 | |
| SCHEMBL19749101 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TSHRFABP7FABP5 | |
| SCHEMBL29433900 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TSHRFABP7FABP5 | |
| SCHEMBL16648788 | 0.81 | ALDH1A1 (0.52) | ALDH1A1TSHRFABP7FABP5 | |
| Bicarbonate SCHEMBL29739771 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008362-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-01-12 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| US-11053209-B2 | Highly efficient synthesis of z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200102285-A1 | A HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYLCES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008362-A1 | COMBINATIONS | WEE2, WEE1, BCL2 | ALDH1A1 2217/4885TSHR 4017/4885FKBP1A 287/4885 |
| US-20200102285-A1 | A HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYLCES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS | ZKSCAN2, ZYX, ZC3H18 | ALDH1A1 4314/4885TSHR 1178/4885FKBP1A 1068/4885 |
| US-11053209-B2 | Highly efficient synthesis of z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | ZKSCAN2, ZYX, SPR | ALDH1A1 4142/4885TSHR 1135/4885FKBP1A 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.